Response Genetics this week named David O'Toole as vice president and chief financial officer.
O'Toole has more than 25 years of accounting and finance experience primarily focused on global companies and the life science and biotechnology industries, Response said. He most recently served as CFO at Abraxis Biosciences. Prior to that, he was a partner at Deloitte & Touche. O'Toole holds a BS degree in accounting from the University of Arizona.
Christian Henry has become general manager of the life sciences business unit of Illumina. Henry's appointment is in addition to his other positions of senior vice president and chief financial officer.
In addition, Illumina has appointed Emily Winn-Deen as vice president for diagnostics development. Winn-Deen will be responsible for developing diagnostics products at Illumina. Previously, she was president of consulting practice Rx Dx Advisors. Before that, she held vice president positions in genetics and oncology R&D, and in strategic development and business planning at Cepheid. In the past, she held senior R&D positions at Roche Molecular Systems, Applera, Oncor, and Bayer Diagnostics. Winn-Deen holds a PhD in chemistry from Boston University and a BA in chemistry from Lehigh University.